Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
Abstract Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which lead to early death due to progressive lung disease. The development of small-molecule modulators that directly interact with CFTR to aid in protein folding (“correctors”) an...
Guardado en:
Autores principales: | Ciaran A. Shaughnessy, Pamela L. Zeitlin, Preston E. Bratcher |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ada0900b04f2474491bb981f326adf27 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio)
por: Mahan Salehi, et al.
Publicado: (2021) -
Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure
por: Heidi J. Nick, et al.
Publicado: (2021) -
Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis
por: Rebecca H. Goldberg, BS, et al.
Publicado: (2021) -
A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor.
por: Jessica E Char, et al.
Publicado: (2014) -
Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis
por: Stéphanie Bui, et al.
Publicado: (2021)